Share Name Share Symbol Market Type Share ISIN Share Description
Hemogenyx LSE:HEMO London Ordinary Share GB00BYX3WZ24 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  +0.30p +11.76% 2.85p 288,968 16:12:03
Bid Price Offer Price High Price Low Price Open Price
2.70p 3.00p 2.85p 2.55p 2.55p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.75 -0.74 10.1

Hemogenyx (HEMO) Latest News

More Hemogenyx News
Hemogenyx Takeover Rumours

Hemogenyx (HEMO) Share Charts

1 Year Hemogenyx Chart

1 Year Hemogenyx Chart

1 Month Hemogenyx Chart

1 Month Hemogenyx Chart

Intraday Hemogenyx Chart

Intraday Hemogenyx Chart

Hemogenyx (HEMO) Discussions and Chat

Hemogenyx Forums and Chat

Date Time Title Posts
12/11/201816:31HEMOGENYX 2018/19 Moderated864
06/11/201807:57Hemogenyx Blockbuster IP licencing to Big Pharma43
28/10/201820:32Davevt2
28/9/201810:36Hemogenyx (HEMO) One to Watch -
10/8/201809:16HEMO824

Add a New Thread

Hemogenyx (HEMO) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:12:002.7060016.20O
16:09:552.7222,278605.96O
16:04:322.902,38169.05O
13:58:072.88212,0666,107.50O
11:45:092.463,08675.76O
View all Hemogenyx trades in real-time

Hemogenyx (HEMO) Top Chat Posts

DateSubject
12/11/2018
08:20
Hemogenyx Daily Update: Hemogenyx is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HEMO. The last closing price for Hemogenyx was 2.55p.
Hemogenyx has a 4 week average price of 2.45p and a 12 week average price of 2.30p.
The 1 year high share price is 6.75p while the 1 year low share price is currently 2.05p.
There are currently 356,042,854 shares in issue and the average daily traded volume is 182,498 shares. The market capitalisation of Hemogenyx is £10,147,221.34.
09/11/2018
15:02
mam fach: Doubt anyone invested here thinks this is short term hold. Neither do they think share price is going to rocket in near future. It's a Buy and Hold.IMHO
06/11/2018
09:04
davevt: You see you rampers are so desperate to shut down and silence anyone with a differing opinion. A differing opinion that the market agrees with, hence why your share price is still dropping. Remember you sad little lot of about 5 forum posters that have some mental affliction to being obsessed about cheerleading your share....no one else agrees with you.
30/10/2018
07:59
pwhite73: You can set up as many threads as you like its the same pattern all over the AIM. The technical progress if any is never reflected in the share price because of how the AIM functions. The company listed on 05/10/2017. A year later no progress has been made on the share price. Whether or not any real progress is being made technically nobody here is in a position to judge. AIM pharmas are masters at bamboozling mug investors with technical jargon and worthless collaborations. There is a golden rule with all AIM pharmas - If they were of any value they would be taken out and not still trading on the AIM. I suspect the US parent just sees the AIM as a means of raising free cash at mug PIs expense.
23/10/2018
08:34
davevt: Badger, how many companies like that throw out leaked tweets to pump share prices, file 'provisional' patent applications which are not patent applications at all in a way to pump share prices, how many companies after getting a client then tell their investors they sucked in on the pump that they are now slicing and dicing any revenues between shell companies. It doesn't matter the credentials, it doesn't matter how good the product is, what matters to share holders is the bottom line. Currently you have no cash, just share options, which aren't even directly held by the main company now, you have a product sans patent, and you have two big deals according to you which actually dropped the share price and only a handful of people were interested. Go and argue with the market, I'm just the messenger.
22/10/2018
00:15
davevt: I've given enough reasons not to buy, so why would I want to buy? I said above it's to tell people to tread with caution. Regarding 'invested people', I've already had one very active poster on here who makes out they are pro hemo message me saying 'keep up the good work because I'm after a cheaper entry and investigate more into previous bankruptcies' This is the stupidity of forums. Firstly, to think I'm 'trying' to do anything, and secondly that they think that some posts on a forum are really gonna actually have some bearing on the share price.......but of course they think that, that's why they ramp.
19/9/2018
20:38
tullynessle: I don't believe it was the tweet. Hemogenyx were speaking recently at the "From Laboratory to Clinic: Accelerating Experimental Medicine Approaches" conference (Sept 4 thru Sept 7), at Trinity College, Oxford. Is it possible that their presentation updated/influenced the conference audience? More details in the posts dated 3 Sept and copied below. Tullynessle 3 Sep '18 - 20:31 - 494 of 539 Edit 0 0 0 Of the thirty one (31) confirmed speakers at the "From Laboratory to Clinic: Accelerating Experimental Medicine Approaches" conference (Sept 4 thru Sept 7), - 28 speakers represent international Universities & Medical/Research Institutes - 1 speaker represents SomaLogic [https://somalogic.com/] - 1 speaker represents Genentech a Member of the Roche Group [https://www.gene.com/] - 1 speaker represents HemoGenyx [https://www.hemogenyx.com/home/default.aspx] I suspect that all is well earned recognition for Dr Vladislav Sandler Ph.D. and the Hemogenyx team. Extract: CONFIRMED SPEAKERS *Bob Anderson (Walter and Eliza Hall Institute, AU) *Pamela Bjorkman (Caltech, USA) *Helen Blau (Stanford University, UA) *Jeffrey Bluestone (UCSF, USA) *Christopher Buckley (University of Oxford, UK) *Dennis Burton (Scripps Research Institute, USA) *Calliope Dendrou (University of Oxford, UK) *Peter Donnelly (University of Oxford, UK) *Kevan Herold (Yale University, USA) *Richard Hodes (NIH National Institute on Aging, USA) *Nebojsa Janjic (Somalogic, USA) *Yvonne Jones (University of Oxford, UK) *Luke Jostins-Dean (University of Oxford, UK) *Carl June (University of Pennsylvania, USA) (TBC) *Michael Karin (UCSD, USA) *Purvesh Khatri (Stanford University, USA) *Simon Leedham (University of Oxford) *Francis Lund (University of Alabama at Birmingham, USA) *Ira Mellman (Genentech, USA) *Michel Nussenzweig (Rockefeller University, USA) *Jeffrey Ravetch (Rockefeller University, USA) *Soumya Raychaudhuri (Harvard Medical School, USA) *Alexander Rudensky (Memorial Sloan Kettering Cancer Centre, USA) *Vladislav Sandler (HemoGenyx) *Owen Sansom (University of Glasgow, UK) *Lawrence Steinmam (Stanford University, USA) *Gitta Stockinger (Crick, UK) *Sarah Teichmann (Wellcome Sanger Institute, UK) *Craig Thompson (Memorial Sloan Kettering Cancer Centre, USA) (TBC) *Carola Vinuesa (ANU College of Health & Medicine, AU) *Georg Wick (Medizinische Universität Innsbruck, AT) https://www.kennedy.ox.ac.uk/more-events/2018-from-lab-to-clinic KENNEDY INSTITUTE OF RHEUMATOLOGY From Laboratory to Clinic: Accelerating Experimental Medicine Approaches Tuesday, 04 September 2018 to Friday, 07 September 2018 Trinity College, Oxford From Laboratory to Clinic is an annual translational research conference established in 1984. It is organised by an international committee led by past and present Directors of the Kennedy Institute, Profs Sir Marc Feldmann, Sir Ravinder Maini and Fiona Powrie. The meeting brings together basic scientists, clinicians, and industry researchers to explore how the latest discoveries in immunology and molecular medicine can be applied to improve clinical medicine. TOPICS * Artificial Intelligence * Immune Regulation * Genetics/Genomics * Inflammation, Repair and Cancer * B cells: Basic to Clinical * Experimental Medicine Continued..... Tullynessle3 Sep '18 - 20:33 - 495 of 539 Edit 0 0 0 Re Post 494 https://uk.advfn.com/stock-market/london/hemogenyx-HEMO/share-news/Hemogenyx-Pharmaceuticals-PLC-Hemogenyx-to-present/78177372 Hemogenyx Pharmaceuticals PLC Hemogenyx to present at Oxford conference 03/09/2018 7:00am UK Regulatory (RNS & others) Hemogenyx to Present at the 'From Laboratory to Clinic' Translational Research Conference in Oxford Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the Standard Listed biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that its CEO, Dr. Vladislav Sandler, will present at the Kennedy Institute of Rheumatology conference 'From Laboratory to Clinic: Accelerating Experimental Medicine Approaches' taking place at Trinity College, Oxford, from Tuesday 4 September until Friday 7 September 2018. Continued.....
19/9/2018
19:08
badger60: Today's share price action has confirmed two things for me.........that Hemogenyx isn't not below the radar, and that the issue of any type of substantively positive RNS will have a significantly beneficial effect on the share price. I firmly believe that patience by shareholders here is going to be extremely well rewarded.......
03/9/2018
19:33
tullynessle: Re Post 494 https://uk.advfn.com/stock-market/london/hemogenyx-HEMO/share-news/Hemogenyx-Pharmaceuticals-PLC-Hemogenyx-to-present/78177372 Hemogenyx Pharmaceuticals PLC Hemogenyx to present at Oxford conference 03/09/2018 7:00am UK Regulatory (RNS & others) Hemogenyx to Present at the 'From Laboratory to Clinic' Translational Research Conference in Oxford Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the Standard Listed biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that its CEO, Dr. Vladislav Sandler, will present at the Kennedy Institute of Rheumatology conference 'From Laboratory to Clinic: Accelerating Experimental Medicine Approaches' taking place at Trinity College, Oxford, from Tuesday 4 September until Friday 7 September 2018. Continued.....
27/6/2018
11:08
badger60: My friend, a significant HEMO shareholder, attended yesterday and sent me this last night.....My question on monetizing mice went down well the answer is that $375k already this year and $3 m in three years and $4m in five years. This will reduce cash burn to zero . Car-t and hemogenyx are totally separate for different cancers and one cannot be used to treat the same cancer as Hemo are targeting as the delivery systems are totally different. Hemo uses antibodies which are 100 smaller and more deliverable than a t cell. Sanofi Roche and Pfizer are the only companies that fit the market cap that is eluded to as being big enough for the tie up to get Hemogenyx list of antibodies to get FDA approval. The company will collaborate with Hemogenyx and pay the cost of obtaining approval so negating the need for massive rights issue. Hemogenyx royalties will be a lot less but say 10%. An example is AML which is expected to cost .5m dollars per course and 10m expected cases in the states gives $5m a patient may need multiple courses say only 2 that's 10m in the states and roughly same for europe so one antibody upwards of $20m and say they get 10% that's $2bn per antibody to Hemogenyx year after year. It's not difficult to see that in five years time the income could be the same as the current market cap. Then times that by the large number of antibodies and the sky's the limit! A cautionary note Hemogenyx was reversed into a fintech company and coo reckons half free float of 100m shares are in weak hands and are sellers at 5-6p so they get out flat from the original company once they are gone in estimated 1 year then they believe share price will be 9-10 p. All of this is subject to filing at the fda and i think it will be around 12p on that news!! I have a presentation pack which i can photo and send but it is no extra news than you already know.
21/3/2018
18:23
pwhite73: OT The nominal value is 1p but when or if shares are issued the company can issue shares at a price of 1p or £10.00 if the share price is high enough. When looking at the possible issuance of new shares you need to look at the current share price and the nominal value. The current share price is 2.45p. What that means is if they were to issue shares at a discount the new shares will not be too far from 1p the nominal value. If the shares were currently trading at £10.00 then the nominal value of 1p and the new shares being priced at 1p would not be a matter of concern for anybody. I hope I've made it clear why I'm rabbiting on about a share issue at 1p the same as the nominal price of 1p.
Hemogenyx share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20181112 20:48:39